title: The long-term outcome of patients with polycystic liver disease treated with lanreotide.
abstract: BACKGROUND
  Polycystic liver disease (PLD) is a phenotypical expression of autosomal dominant polycystic kidney disease and isolated polycystic liver disease. Somatostatin analogues, such as lanreotide, reduce polycystic liver volume.
  
  
  OBJECTIVE
  To establish long-term outcome and safety of lanreotide.
  
  
  METHODS
  This was an open-label, observational extension study of a 6-month, randomised, placebo-controlled trial with lanreotide (120 mg/month) in PLD. The length of total treatment was 12 months. Primary endpoint was relative change in liver volume, as determined by CT-volumetry after 12 months of treatment. We offered patients a CT scan 6 months after stopping lanreotide.
  
  
  RESULTS
  A total of 41/54 (76%) patients participated in the extension study. Liver volume decreased by 4% (IQR -8% to -1%) after 12 months of treatment. The greatest effect was observed during the first 6 months of treatment (decrease of 4% (IQR -6% to -1%)). Liver volume remained unchanged during the following 6 months. We found that liver volume increased by 4% (IQR 0-6%) 6 months after end of treatment (n = 22).
  
  
  CONCLUSIONS
  Lanreotide reduces liver volume within the first 6 months of treatment and the beneficial effect is maintained in the following 6 months. Stopping results in recurrence of polycystic liver growth. This suggests that continuous use of lanreotide is needed to maintain its effect.
authors: Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, The Netherlands.
authors: M
authors: M
authors: Chrispijn
authors: F
authors: F
authors: Nevens
authors: T J G
authors: TJ
authors: Gevers
authors: R
authors: R
authors: Vanslembrouck
authors: M G H
authors: MG
authors: van Oijen
authors: W
authors: W
authors: Coudyzer
authors: A L
authors: AL
authors: Hoffmann
authors: H M
authors: HM
authors: Dekker
authors: R A
authors: RA
authors: de Man
authors: L
authors: L
authors: van Keimpema
authors: J P H
authors: JP
authors: Drenth
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003560:Cysts / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D008099:Liver / Q000187:drug effects; D008107:Liver Diseases / Q000188:drug therapy* / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013223:Statistics as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin